CareLit · DOI-Nachweis · Pneumologie
Safety of aclidinium bromide/formoterol fumarate fixed-dose combination in COPD: pooled analyses of three Phase III studies
DOI 10.1055/s-0035-1544790
Bibliografische Angaben
Nachweis in CareLit
Autor:innenS Korn, E Kerwin, JF Donohue, P Shrestha, A Leselbaum, A Lei
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Two 24-week Phase III studies (ACLIFORM and AUGMENT) and a 28-week AUGMENT extension study assessed the efficacy and safety of two twice-daily aclidinium/formoterol fixed-dose combinations (FDC) in patients with moderate-to-severe COPD. Aim: To assess adverse events (AEs) in a pooled analysis of the three Phase III studies. Methods: The studies were randomized, double-blind, placebo- and active-controlle…
Zitieren
Zitierempfehlung
S Korn, E Kerwin, JF Donohue, P Shrestha, A Leselbaum, A Lei (2015) Safety of aclidinium bromide/formoterol fumarate fixed-dose combination in COPD: pooled analyses of three Phase III studies. Pneumologie (02). https://doi.org/10.1055/s-0035-1544790
Mit CareLit weiterarbeiten